Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer

Table 1 Clinicopathological characteristics of patients stratified by HR and HER2 status on primary breast cancer

	HR+HER2-zero		HR+HER2-low		HR+HER2+		p value	HR−HER2-zero		HR−HER2-low		HR−HER2+		P value
	N = 100		N = 93		N = 42			N = 137		N = 53		N = 108		P value
Age, years
≤ 45	53	53.00%	53	56.99%	20	47.62%	P vs L: ns Z vs L: ns	74	54.02%	27	50.94%	44	40.74%	P vs L: ns Z vs L: ns
> 45	47	47.00%	40	43.01%	22	52.38%	P vs L: ns Z vs L: ns	63	45.96%	26	49.06%	64	59.26%	P vs L: ns Z vs L: ns
T stage
pT1	28	40.00%	22	40.00%	9	34.62%	P vs L: ns Z vs L: ns	29	27.88%	14	35.90%	19	27.14%	P vs L: ns Z vs L: ns
pT2	38	54.29%	31	56.36%	13	50.00%		65	62.50%	22	56.41%	44	62.86%
pT3-4	4	5.71%	2	3.64%	4	15.38%		10	9.62%	3	7.69%	7	10.00%
N stage
pN0	26	30.59%	27	39.13%	7	23.33%	P vs L: ns Z vs L: ns	35	29.66%	17	37.78%	19	23.17%	P vs L: ns Z vs L: ns
pN +	59	69.41%	42	60.87%	23	76.67%	P vs L: ns Z vs L: ns	83	70.34%	28	62.22%	63	76.83%	P vs L: ns Z vs L: ns
Ki 67 percent (%)
≤ 40	68	79.07%	56	74.67%	30	73.17%	P vs L: ns Z vs L: ns	44	34.65%	17	36.17%	61	60.40%	P vs L: 0.006 Z vs L: ns
> 40	18	20.93%	19	25.33%	11	26.83%	P vs L: ns Z vs L: ns	83	65.35%	30	63.83%	40	39.60%	P vs L: 0.006 Z vs L: ns
Pathology grade
I–II	48	62.34%	42	65.63%	13	46.43%	P vs L: ns Z vs L: ns	24	23.08%	14	32.56%	29	36.25%	P vs L: ns Z vs L: ns
III	29	37.66%	22	34.37%	15	53.57%	P vs L: ns Z vs L: ns	80	76.92%	29	67.44%	51	63.75%	P vs L: ns Z vs L: ns
De novo stage IV breast cancer
Early	93	93.00%	73	78.49%	30	71.43%	P vs L: ns Z vs L: 0.004	124	90.51%	46	86.79%	86	79.63%	P vs L: ns Z vs L: ns
Advanced	7	7.00%	20	21.51%	12	28.57%	P vs L: ns Z vs L: 0.004	13	9.49%	7	13.21%	22	20.37%	P vs L: ns Z vs L: ns

Bold value indicates the siginificant P values
HER2−: HER2-negative; HER2+: HER2-positive; HR−: HR-negative; HR+: HR-positive; P: HER2-positive; L: HER2-low; Z: HER2-zero;
The P value was calculated by Chi-square test

ISSN: 1479-5876